Angiotensin II receptor / Calcium channel / HMG-CoA reductase

Class

ARB + CCB + statin triple fixed-dose combination

This fixed-dose combination brings together three drug classes that act on separate physiological systems to lower cardiovascular risk factors simultaneously. An angiotensin II receptor blocker (ARB) prevents the hormone angiotensin II from binding its receptor on blood vessel walls, reducing vasoconstriction and blood pressure. A calcium channel blocker (CCB) limits calcium entry into vascular smooth muscle cells, causing vessels to relax through a distinct, complementary mechanism. An HMG-CoA reductase inhibitor, or statin, blocks a rate-limiting enzyme in cholesterol synthesis in the liver, lowering circulating low-density lipoprotein (LDL) cholesterol. Individually, each class addresses a major, independent driver of cardiovascular disease: hypertension from two different physiological angles, and atherogenic lipid levels from a third. Combining them into one product is a pharmacological strategy aimed at treating multiple risk factors that commonly coexist in the same patient, particularly in long-term prevention of heart attack and stroke. This class of triple combination reflects a broader rationale in chronic disease management: reducing the number of separate medications a person must take can improve consistency of use, since blood pressure and cholesterol control both depend on sustained, daily therapy rather than intermittent dosing.